CHEK2 and hereditary cancer: Thus, it may be possible to selectively target familial cancers as the non-cancerous (i.e. normal) cells are expected to harbor a single wild-type copy of BLM or CHEK2, and produce sufficient protein to render these cells resistant to a SL attack.